ReviewBiomedical engineering letters2026
Phase-change perfluorocarbon nanodroplets enable spatiotemporal control of ultrasound and photoacoustic imaging and therapy.
Review in Biomedical engineering letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phase-change perfluorocarbon nanodroplets (PFCnDs) are submicrometer, liquid-core agents capable of generating strong ultrasound (US) and photoacoustic contrast following external stimulation. This selective vaporization allows site-specific signal generation and facilitates imaging beyond the vascular compartment. The behavior of PFCnDs is determined by a thermodynamic landscape in which Laplace pressure and nucleation kinetics jointly influence vaporization thresholds and post-vaporization outcomes, including persistent gas bubble formation or rapid recondensation. This review summarizes the mechanistic framework underlying acoustic droplet vaporization, optical droplet vaporization, and combined optical-acoustic droplet vaporization of PFCnDs. These phase-change mechanisms are discussed in relation to formulation variables such as perfluorocarbon species, size distribution, shell mechanics, and absorber loading, as well as exposure conditions including acoustic pressure, frequency, pulse structure, and optical fluence. The review further examines how these coupled parameters govern vaporization dynamics, imaging persistence, and associated bioeffects. Imaging applications, including contrast-enhanced US, extravascular and lymphatic imaging, super-resolution, and multiplexed approaches that leverage vaporization-recondensation behavior, are surveyed. Therapeutic applications, such as drug delivery and barrier-opening techniques, are also examined alongside clinical translation priorities, including manufacturing, in vivo fate verification, reproducible vaporization, and standardized safety dosimetry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.